-
Analysis of the MICCAI Brain Tumor Segmentation -- Metastases (BraTS-METS) 2025 Lighthouse Challenge: Brain Metastasis Segmentation on Pre- and Post-treatment MRI
Authors:
Nazanin Maleki,
Raisa Amiruddin,
Ahmed W. Moawad,
Nikolay Yordanov,
Athanasios Gkampenis,
Pascal Fehringer,
Fabian Umeh,
Crystal Chukwurah,
Fatima Memon,
Bojan Petrovic,
Justin Cramer,
Mark Krycia,
Elizabeth B. Shrickel,
Ichiro Ikuta,
Gerard Thompson,
Lorenna Vidal,
Vilma Kosovic,
Adam E. Goldman-Yassen,
Virginia Hill,
Tiffany So,
Sedra Mhana,
Albara Alotaibi,
Nathan Page,
Prisha Bhatia,
Yasaman Sharifi
, et al. (218 additional authors not shown)
Abstract:
Despite continuous advancements in cancer treatment, brain metastatic disease remains a significant complication of primary cancer and is associated with an unfavorable prognosis. One approach for improving diagnosis, management, and outcomes is to implement algorithms based on artificial intelligence for the automated segmentation of both pre- and post-treatment MRI brain images. Such algorithms…
▽ More
Despite continuous advancements in cancer treatment, brain metastatic disease remains a significant complication of primary cancer and is associated with an unfavorable prognosis. One approach for improving diagnosis, management, and outcomes is to implement algorithms based on artificial intelligence for the automated segmentation of both pre- and post-treatment MRI brain images. Such algorithms rely on volumetric criteria for lesion identification and treatment response assessment, which are still not available in clinical practice. Therefore, it is critical to establish tools for rapid volumetric segmentations methods that can be translated to clinical practice and that are trained on high quality annotated data. The BraTS-METS 2025 Lighthouse Challenge aims to address this critical need by establishing inter-rater and intra-rater variability in dataset annotation by generating high quality annotated datasets from four individual instances of segmentation by neuroradiologists while being recorded on video (two instances doing "from scratch" and two instances after AI pre-segmentation). This high-quality annotated dataset will be used for testing phase in 2025 Lighthouse challenge and will be publicly released at the completion of the challenge. The 2025 Lighthouse challenge will also release the 2023 and 2024 segmented datasets that were annotated using an established pipeline of pre-segmentation, student annotation, two neuroradiologists checking, and one neuroradiologist finalizing the process. It builds upon its previous edition by including post-treatment cases in the dataset. Using these high-quality annotated datasets, the 2025 Lighthouse challenge plans to test benchmark algorithms for automated segmentation of pre-and post-treatment brain metastases (BM), trained on diverse and multi-institutional datasets of MRI images obtained from patients with brain metastases.
△ Less
Submitted 6 May, 2025; v1 submitted 16 April, 2025;
originally announced April 2025.
-
In vivo mapping organellar metabolism by optical-boxcar enhanced fluorescence-detected mid-infrared photothermal microscopy
Authors:
Jianpeng Ao,
Jiaze Yin,
Haonan Lin,
Guangrui Ding,
Youchen Guan,
Bethany Weinberg,
Dashan Dong,
Qing Xia,
Zhongyue Guo,
Marzia Savini,
Biwen Gao,
Ji-Xin Cheng,
Meng C. Wang
Abstract:
Metabolism unfolds within specific organelles in eukaryotic cells. Lysosomes are highly metabolically active organelles, and their metabolic states dynamically influence signal transduction, cellular homeostasis, and organismal physiopathology. Despite the significance of lysosomal metabolism, a method for its in vivo measurement is currently lacking. Here, we report optical boxcar-enhanced, fluor…
▽ More
Metabolism unfolds within specific organelles in eukaryotic cells. Lysosomes are highly metabolically active organelles, and their metabolic states dynamically influence signal transduction, cellular homeostasis, and organismal physiopathology. Despite the significance of lysosomal metabolism, a method for its in vivo measurement is currently lacking. Here, we report optical boxcar-enhanced, fluorescence-detected mid-infrared photothermal microscopy, together with AI-assisted data denoising and spectral deconvolution, to map metabolic activity and composition of individual lysosomes in living cells and organisms. Using this method, we uncovered lipolysis and proteolysis heterogeneity across lysosomes within the same cell, as well as early-onset lysosomal dysfunction during organismal aging. Additionally, we discovered organelle-level metabolic changes associated with diverse lysosomal storage diseases. This method holds the broad potential to profile metabolic fingerprints of individual organelles within their native context and quantitatively assess their dynamic changes under different physiological and pathological conditions, providing a high-resolution chemical cellular atlas.
△ Less
Submitted 5 April, 2025;
originally announced April 2025.
-
The 2024 Brain Tumor Segmentation (BraTS) Challenge: Glioma Segmentation on Post-treatment MRI
Authors:
Maria Correia de Verdier,
Rachit Saluja,
Louis Gagnon,
Dominic LaBella,
Ujjwall Baid,
Nourel Hoda Tahon,
Martha Foltyn-Dumitru,
Jikai Zhang,
Maram Alafif,
Saif Baig,
Ken Chang,
Gennaro D'Anna,
Lisa Deptula,
Diviya Gupta,
Muhammad Ammar Haider,
Ali Hussain,
Michael Iv,
Marinos Kontzialis,
Paul Manning,
Farzan Moodi,
Teresa Nunes,
Aaron Simon,
Nico Sollmann,
David Vu,
Maruf Adewole
, et al. (60 additional authors not shown)
Abstract:
Gliomas are the most common malignant primary brain tumors in adults and one of the deadliest types of cancer. There are many challenges in treatment and monitoring due to the genetic diversity and high intrinsic heterogeneity in appearance, shape, histology, and treatment response. Treatments include surgery, radiation, and systemic therapies, with magnetic resonance imaging (MRI) playing a key r…
▽ More
Gliomas are the most common malignant primary brain tumors in adults and one of the deadliest types of cancer. There are many challenges in treatment and monitoring due to the genetic diversity and high intrinsic heterogeneity in appearance, shape, histology, and treatment response. Treatments include surgery, radiation, and systemic therapies, with magnetic resonance imaging (MRI) playing a key role in treatment planning and post-treatment longitudinal assessment. The 2024 Brain Tumor Segmentation (BraTS) challenge on post-treatment glioma MRI will provide a community standard and benchmark for state-of-the-art automated segmentation models based on the largest expert-annotated post-treatment glioma MRI dataset. Challenge competitors will develop automated segmentation models to predict four distinct tumor sub-regions consisting of enhancing tissue (ET), surrounding non-enhancing T2/fluid-attenuated inversion recovery (FLAIR) hyperintensity (SNFH), non-enhancing tumor core (NETC), and resection cavity (RC). Models will be evaluated on separate validation and test datasets using standardized performance metrics utilized across the BraTS 2024 cluster of challenges, including lesion-wise Dice Similarity Coefficient and Hausdorff Distance. Models developed during this challenge will advance the field of automated MRI segmentation and contribute to their integration into clinical practice, ultimately enhancing patient care.
△ Less
Submitted 28 May, 2024;
originally announced May 2024.
-
The Brain Tumor Segmentation (BraTS-METS) Challenge 2023: Brain Metastasis Segmentation on Pre-treatment MRI
Authors:
Ahmed W. Moawad,
Anastasia Janas,
Ujjwal Baid,
Divya Ramakrishnan,
Rachit Saluja,
Nader Ashraf,
Nazanin Maleki,
Leon Jekel,
Nikolay Yordanov,
Pascal Fehringer,
Athanasios Gkampenis,
Raisa Amiruddin,
Amirreza Manteghinejad,
Maruf Adewole,
Jake Albrecht,
Udunna Anazodo,
Sanjay Aneja,
Syed Muhammad Anwar,
Timothy Bergquist,
Veronica Chiang,
Verena Chung,
Gian Marco Conte,
Farouk Dako,
James Eddy,
Ivan Ezhov
, et al. (207 additional authors not shown)
Abstract:
The translation of AI-generated brain metastases (BM) segmentation into clinical practice relies heavily on diverse, high-quality annotated medical imaging datasets. The BraTS-METS 2023 challenge has gained momentum for testing and benchmarking algorithms using rigorously annotated internationally compiled real-world datasets. This study presents the results of the segmentation challenge and chara…
▽ More
The translation of AI-generated brain metastases (BM) segmentation into clinical practice relies heavily on diverse, high-quality annotated medical imaging datasets. The BraTS-METS 2023 challenge has gained momentum for testing and benchmarking algorithms using rigorously annotated internationally compiled real-world datasets. This study presents the results of the segmentation challenge and characterizes the challenging cases that impacted the performance of the winning algorithms. Untreated brain metastases on standard anatomic MRI sequences (T1, T2, FLAIR, T1PG) from eight contributed international datasets were annotated in stepwise method: published UNET algorithms, student, neuroradiologist, final approver neuroradiologist. Segmentations were ranked based on lesion-wise Dice and Hausdorff distance (HD95) scores. False positives (FP) and false negatives (FN) were rigorously penalized, receiving a score of 0 for Dice and a fixed penalty of 374 for HD95. Eight datasets comprising 1303 studies were annotated, with 402 studies (3076 lesions) released on Synapse as publicly available datasets to challenge competitors. Additionally, 31 studies (139 lesions) were held out for validation, and 59 studies (218 lesions) were used for testing. Segmentation accuracy was measured as rank across subjects, with the winning team achieving a LesionWise mean score of 7.9. Common errors among the leading teams included false negatives for small lesions and misregistration of masks in space.The BraTS-METS 2023 challenge successfully curated well-annotated, diverse datasets and identified common errors, facilitating the translation of BM segmentation across varied clinical environments and providing personalized volumetric reports to patients undergoing BM treatment.
△ Less
Submitted 8 December, 2024; v1 submitted 1 June, 2023;
originally announced June 2023.
-
The RSNA-ASNR-MICCAI BraTS 2021 Benchmark on Brain Tumor Segmentation and Radiogenomic Classification
Authors:
Ujjwal Baid,
Satyam Ghodasara,
Suyash Mohan,
Michel Bilello,
Evan Calabrese,
Errol Colak,
Keyvan Farahani,
Jayashree Kalpathy-Cramer,
Felipe C. Kitamura,
Sarthak Pati,
Luciano M. Prevedello,
Jeffrey D. Rudie,
Chiharu Sako,
Russell T. Shinohara,
Timothy Bergquist,
Rong Chai,
James Eddy,
Julia Elliott,
Walter Reade,
Thomas Schaffter,
Thomas Yu,
Jiaxin Zheng,
Ahmed W. Moawad,
Luiz Otavio Coelho,
Olivia McDonnell
, et al. (78 additional authors not shown)
Abstract:
The BraTS 2021 challenge celebrates its 10th anniversary and is jointly organized by the Radiological Society of North America (RSNA), the American Society of Neuroradiology (ASNR), and the Medical Image Computing and Computer Assisted Interventions (MICCAI) society. Since its inception, BraTS has been focusing on being a common benchmarking venue for brain glioma segmentation algorithms, with wel…
▽ More
The BraTS 2021 challenge celebrates its 10th anniversary and is jointly organized by the Radiological Society of North America (RSNA), the American Society of Neuroradiology (ASNR), and the Medical Image Computing and Computer Assisted Interventions (MICCAI) society. Since its inception, BraTS has been focusing on being a common benchmarking venue for brain glioma segmentation algorithms, with well-curated multi-institutional multi-parametric magnetic resonance imaging (mpMRI) data. Gliomas are the most common primary malignancies of the central nervous system, with varying degrees of aggressiveness and prognosis. The RSNA-ASNR-MICCAI BraTS 2021 challenge targets the evaluation of computational algorithms assessing the same tumor compartmentalization, as well as the underlying tumor's molecular characterization, in pre-operative baseline mpMRI data from 2,040 patients. Specifically, the two tasks that BraTS 2021 focuses on are: a) the segmentation of the histologically distinct brain tumor sub-regions, and b) the classification of the tumor's O[6]-methylguanine-DNA methyltransferase (MGMT) promoter methylation status. The performance evaluation of all participating algorithms in BraTS 2021 will be conducted through the Sage Bionetworks Synapse platform (Task 1) and Kaggle (Task 2), concluding in distributing to the top ranked participants monetary awards of $60,000 collectively.
△ Less
Submitted 12 September, 2021; v1 submitted 5 July, 2021;
originally announced July 2021.
-
SAGE: Sequential Attribute Generator for Analyzing Glioblastomas using Limited Dataset
Authors:
Padmaja Jonnalagedda,
Brent Weinberg,
Jason Allen,
Taejin L. Min,
Shiv Bhanu,
Bir Bhanu
Abstract:
While deep learning approaches have shown remarkable performance in many imaging tasks, most of these methods rely on availability of large quantities of data. Medical image data, however, is scarce and fragmented. Generative Adversarial Networks (GANs) have recently been very effective in handling such datasets by generating more data. If the datasets are very small, however, GANs cannot learn th…
▽ More
While deep learning approaches have shown remarkable performance in many imaging tasks, most of these methods rely on availability of large quantities of data. Medical image data, however, is scarce and fragmented. Generative Adversarial Networks (GANs) have recently been very effective in handling such datasets by generating more data. If the datasets are very small, however, GANs cannot learn the data distribution properly, resulting in less diverse or low-quality results. One such limited dataset is that for the concurrent gain of 19 and 20 chromosomes (19/20 co-gain), a mutation with positive prognostic value in Glioblastomas (GBM). In this paper, we detect imaging biomarkers for the mutation to streamline the extensive and invasive prognosis pipeline. Since this mutation is relatively rare, i.e. small dataset, we propose a novel generative framework - the Sequential Attribute GEnerator (SAGE), that generates detailed tumor imaging features while learning from a limited dataset. Experiments show that not only does SAGE generate high quality tumors when compared to standard Deep Convolutional GAN (DC-GAN) and Wasserstein GAN with Gradient Penalty (WGAN-GP), it also captures the imaging biomarkers accurately.
△ Less
Submitted 3 June, 2022; v1 submitted 14 May, 2020;
originally announced May 2020.
